Dr Sallman on the Rationale For Investigating Fedratinib in MDS/MPN Overlap Syndromes
January 4th 2024
David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.